CrystalsFirst is a hybrid platform pioneering the discovery and development of small molecule drugs for challenging targets. The company disrupts the access to bio-structural data using its proprietary high-performance crystallography technologies and links structural data with large-scale chemoinformatics and AI. As a result, the rapid exploration of the chemical space is guided by structural data, efficiently leading to tailored actives, hence, increasing the returns on R&D investments.